| Previous Close | 11.24 |
| Open | 11.24 |
| Bid | 10.65 x 100 |
| Ask | 13.00 x 300 |
| Day's Range | 11.04 - 11.32 |
| 52 Week Range | 4.88 - 12.04 |
| Volume | 170,607 |
| Avg. Volume | 254,564 |
| Market Cap | 514.19M |
| Beta | 0.90 |
| PE Ratio (TTM) | 15.54 |
| EPS (TTM) | 0.71 |
| Earnings Date | Jun 9, 2017 - Jun 12, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.00 |
- Zacks•2 days ago
Geron's (GERN) Imetelstat Progressing Well, Setbacks Concern
Geron Corporation's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies. The candidate is progressing well in the Janssen sponsored studies.
- Thomson Reuters StreetEvents•5 days ago
Edited Transcript of ENZ earnings conference call or presentation 9-Jun-17 12:30pm GMT
Q3 2017 Enzo Biochem Inc Earnings Call
- Zacks•6 days ago
Catalyst (CPRX) Posts Narrower than Expected Loss in Q2
Catalyst Pharmaceuticals, Inc. (CPRX) reported narrower than expected loss in Q2 and is focused on the development of its pipeline candidate Firdapse.
